Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition

被引:19
|
作者
Jin, Hyeon-Ok [1 ]
Lee, Yun-Han [2 ]
Park, Jin-Ah [1 ]
Kim, Jin-Hee [1 ]
Hong, Sung-Eun [3 ]
Kim, Hyun-Ah [4 ]
Kim, Eun-Kyu [4 ]
Noh, Woo Chul [4 ]
Kim, Byung-Hak [5 ]
Ye, Sang-Kyu [5 ]
Chang, Yoon Hwan [6 ]
Hong, Seok-Il [6 ]
Hong, Young-Joon [6 ]
Park, In-Chul [3 ]
Lee, Jin Kyung [1 ]
机构
[1] Korea Inst Radiol & Med Sci, KIRAMS Radiat Blood Specimen Biobank, Seoul 139709, South Korea
[2] Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul 120752, South Korea
[3] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea
[4] Korea Inst Radiol & Med Sci, Dept Surg, Korea Canc Ctr Hosp, Seoul 139706, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea
[6] Korea Inst Radiol & Med Sci, Dept Lab Med, Korea Canc Ctr Hosp, Seoul 139709, South Korea
关键词
Akt; Bim; CHOP; mTOR; PI3K; Stat3; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; SIGNAL TRANSDUCER; CANCER; NVP-BEZ235; ACTIVATION; APOPTOSIS; PATHWAY; LEADS; PTEN;
D O I
10.1016/j.bbrc.2014.01.086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K/Akt/mTOR axis in lung cancer is frequently activated and implicated in tumorigenesis. Specific targeting of this pathway is therefore an attractive therapeutic approach for lung cancer. However, non-small cell lung cancer cells are resistant to BEZ235, a dual inhibitor of PI3K and mTOR. Interestingly, blockage of Stat3 with a selective inhibitor, S3I-201, or siRNA dramatically sensitized the BEZ235-induced cell death, as evident from increased PARP cleavage. Furthermore, inhibition of Stat3 led to enhancement of cell death induced by LY294002, a PI3K inhibitor. Treatment of cells with a combination of BEZ235 and S3I-201 significantly induced the proapoptotic transcription factor, CHOP, and its targets, Bim and DR4. Knockdown of CHOP or Bim suppressed cell death stimulated by the combination treatment, implicating the involvement of these BEZ235/S3I-201-induced factors in pronounced cell death. Moreover, the BEZ235/S3I-201 combination enhanced TRAIL-induced cell death. Our results collectively suggest that blockage of Stat3 presents an effective strategy to overcome resistance to PI3K/Akt/mTOR inhibition. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:502 / 508
页数:7
相关论文
共 50 条
  • [41] MAPkinase and PI3K/mTOR pathways inhibition in conjunctival melanoma
    Ei-Zaoui, Ikram El Zaoui
    Nicolas, Michael
    Gobert, Rosanna Pescini
    Rimoldi, Donata
    Leyraz, Serge
    Rivolta, Carlo
    Moulin, Alexandre
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [42] In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
    Heavey, Susan
    Cuffe, Sinead
    Finn, Stephen
    Young, Vincent
    Ryan, Ronan
    Nicholson, Siobhan
    Leonard, Niamh
    McVeigh, Niall
    Barr, Martin
    O'Byrne, Kenneth
    Gately, Kathy
    ONCOTARGET, 2016, 7 (48) : 79512 - 79529
  • [43] Resistance to Cisplatin in NSCLC is Related to Autophagy Induced by PI3K/AKT/mTOR Signaling Pathway Inhibition
    Peng, Ling
    Miao, Ya-Fang
    Chen, Hao
    Wang, Qiu-Bo
    Wang, An
    Xue, Fei
    Zhou, Chao
    LATIN AMERICAN JOURNAL OF PHARMACY, 2020, 39 (03): : 482 - 489
  • [44] PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells
    Marklein, Diana
    Graab, Ulrike
    Naumann, Ivonne
    Yan, Tiandong
    Ridzewski, Rosalie
    Nitzki, Frauke
    Rosenberger, Albert
    Dittmann, Kai
    Wienands, Juergen
    Wojnowski, Leszek
    Fulda, Simone
    Hahn, Heidi
    PLOS ONE, 2012, 7 (12):
  • [45] Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models
    Powley, Ian
    Galavotti, Sara
    Sun, Xiao-Ming
    Chernova, Tatyana
    Nakas, Apostolos
    Le Quesne, John
    Pringle, Howard
    Fennell, Dean
    MacFarlane, Marion
    TOXICOLOGY LETTERS, 2014, 229 : S153 - S153
  • [46] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [47] Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro
    Cai, Yunlang
    Tan, Xiaoqiang
    Liu, Jun
    Shen, Yang
    Wu, Di
    Ren, Mulan
    Huang, Peilin
    Yu, Dandan
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (05) : 564 - 572
  • [48] Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
    Chanal, Marie
    Chevallier, Pascale
    Raverot, Veronique
    Fonteneau, Guillaume
    Lucia, Kristin
    Garcia, Jose Luis Monteserin
    Rachwan, Alexa
    Jouanneau, Emmanuel
    Trouillas, Jacqueline
    Honnorat, Jerome
    Auger, Carole
    Theodoropoulou, Marily
    Raverot, Gerald
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (06) : 1261 - 1270
  • [49] Inhibition of the PI3K and mTOR survival pathways enhances apoptosis in human mesothelioma tumor fragment spheroids
    Wilson, SM
    Kim, KU
    Abayasiriwardana, KS
    Fjellbirkland, L
    Xu, Z
    Jablons, DM
    Nishimura, SL
    Broaddus, VC
    FASEB JOURNAL, 2006, 20 (05): : A1082 - A1082
  • [50] Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations
    Bonelli, M.
    Cavazzoni, A.
    La Monica, S.
    Galetti, M.
    Caffarra, C.
    Cretella, D.
    Saccani, F.
    Fumarola, C.
    Alfieri, R.
    Petronini, P. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S166 - S167